LEXX
Lexaria Bioscience Corp.
$0.53
-0.03 (-5.36%)
At close · Jul 7
Market Cap
$13.14M
Shares
24,787,446
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.53
Open$0.54
Day$0.53–0.58
52W$0.46–1.55
Avg vol 30d66K
Short int360K · 1.5% float · 4.5d
Short vol68%
DataJan 2021–Jul 2026
Filing10-Q · Apr 13
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−35%
below
Price vs 50-day avg
−15%
below
RSI (14)
38
neutral
MACD trend
Positive
52-week position
6%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−17%
trailing
6-month return
−31%
trailing
YTD return
−14%
this year
Relative strength
−39%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+33% holders QoQ · +10 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
1.45% of float · ▲ +2.9% MoM · 4.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
28 holders — mid 3-yr range
Squeeze score
60
elevated · 0–100
Fundamentals
Revenue growth
+52%
Y/Y
Gross margin
100%
expanding
EPS growth
−40%
Y/Y
Free cash flow
$-10.5M
Balance sheet
$5.8M
net cash
Quant / Vol
risk profile
Volatility
103%
annualized · 1-yr
Max drawdown
−65%
past year
ATR
8.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
FQ4-26 quarter ends
~Aug 31, 2026
Est
filed Apr 13, 2026
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−35%
Bearish
Price vs 50-day avg
−15%
Bearish
RSI (14)
38
Neutral
MACD trend
Positive
Bullish
52-week position
6%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+33% holders QoQ · +10 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
1.45% of float · ▲ +2.9% MoM · 4.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
28 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $0
Now $1 · 6%
52-wk high $2
vs 200-day avg -35%
vs 50-day avg -15%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LEXX
this stock
Lexaria Bioscience Corp.
|
$13.14M | -14.1% | +52.0% | — | 1.5% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.55B | +15.2% | +46.2% | 31.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.90B | -12.3% | +20.8% | 16.5 | 3.2% |
|
ARGX
Argenx SE
|
$57.49B | +9.4% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LEXX | -6.9% | -16.8% | -31.2% | -5.4% | -14.1% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | -7.8% | -18.2% | -38.7% | -5.5% | -23.8% |